Vibgyor Scientific Research, genae associates, Cardiovascular Center Aalst and J.B. Dahm will form a core lab. The name: imaeon. It will specialize in medical image analysis from its main facilities in Ahmedabad, India and Antwerp, Belgium.

Medelis has formed Medelis Europe and appointed Deirdre Tessman. “We are excited to take this significant step in expanding our geographical coverage and our service offerings to our worldwide clients, who wish to bring their drugs to the European community,” said Medelis CEO Bob Bosserman. Medelis Europe will deliver complete oncology drug development services from preclinical through Phase III. Sponsors can utilize Medelis’ full service offering, which includes electronic data capture (EDC) for Phase I studies, internet-based patient recruitment and integrated preclinical studies aligning the preclinical, regulatory and clinical teams.

  {embed=“includes/banner_ads” loc=“middle”}

Clinical Research Education and Management Academy has forged an alliance with U.S.-based D. Anderson & Company to conduct a conference on patient recruitment issues. The meeting will be held in Mumbai on November 3 and 4, 2008. Diana Anderson, president and CEO of D. Anderson, will be the faculty advisor to the conference and responsible for providing guidance and content for training. “India anticipates a substantive increase in clinical trials, given global pressure to recruit more patients faster. Currently, there are no formal guidelines detailing acceptable patient recruitment methods. This provides a wealth of educational opportunities,” said Anderson.

Ariad Pharmaceuticals appointed Massimo Radaelli and Wayne Wilson to its board. Radaelli is president and CEO of Dompé International; Wilson is an independent business advisor and certified public accountant. “I am very pleased to have two such outstanding leaders and experts in their respective fields join our board of directors,” said Harvey Berger, chairman and CEO of Ariad. “Massimo is a pharmaceutical executive with an in-depth understanding of global product strategy, drug commercialization and corporate development. Wayne brings extensive experience as a corporate director and executive of public companies and as an audit committee financial expert to our board.”

  {embed=“includes/banner_ads” loc=“third”}

CytoDyn has relocated its business offices to Santa Fe. The company has retained Target Health as its CRO. CytoDyn is also pleased to announce that Parviz Lalezari has joined the Cytodyn’s scientific advisory board.

The Clinical Data Interchange Standards Consortium published the much-awaited version 1.0 of its standard for the structure of case report forms (CRF). Kudos are in order for a large and energetic group of volunteers. The CDASH project, as it’s called, is a landmark effort. It nudges the industry toward more sensible ways of organizing clinical data from the start of a project. Longer term, if adopted in earnest by sponsors, CDASH and the other interlinked CDISC standards have the potential to lower the cost of all trials and radically simplify the cooperation of the myriad technology and service organizations supporting such studies. By baking data standards into the cake from the start, CDASH should also expedite the downstream analysis and review of data, both within the sponsor community and at regulatory agencies. This sort of thing could make a less world-weary journalist a bit damp around the eyes. An earlier ClinPage story.

Have a news release? Send it to .